Form 8-K - Current report:
SEC Accession No. 0001140361-23-043276
Filing Date
2023-09-08
Accepted
2023-09-08 06:02:01
Documents
13
Period of Report
2023-09-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20058596_8k.htm   iXBRL 8-K 28811
2 EXHIBIT 99.1 brhc20058596_ex99-1.htm EX-99.1 15740
  Complete submission text file 0001140361-23-043276.txt   186812

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pdsb-20230906.xsd EX-101.SCH 3871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pdsb-20230906_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pdsb-20230906_pre.xml EX-101.PRE 16048
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc20058596_8k_htm.xml XML 4239
Mailing Address 303A COLLEGE ROAD EAST PRINCETON NJ 08540
Business Address 303A COLLEGE ROAD EAST PRINCETON NJ 08540 800-208-3343
PDS Biotechnology Corp (Filer) CIK: 0001472091 (see all company filings)

EIN.: 264231384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37568 | Film No.: 231243624
SIC: 2834 Pharmaceutical Preparations